We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER’s 2018 Guidance Agenda Features Gene Therapies
CBER’s 2018 Guidance Agenda Features Gene Therapies
CBER’s agenda for 2018 states that it is considering the release of more than a dozen guidance documents, including new draft guidance on testing retroviral gene therapy products and on hemophilia gene therapy, along with revisions to its draft guidance on reducing the risk of Zika virus transmission.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor